Mitchell Mutz, Ph.D.

Chief Financial Officer

Mitchell Mutz is the Chief Financial Officer (interim) and Board member at EpiBiologics. Mitchell is an accomplished venture investor, biotech serial entrepreneur and inventor. He is currently Entrepreneur Partner at Vivo Capital, focusing on early-stage investment opportunities in therapeutics and company creation. He currently serves on the boards of EpiBiologics, Bonum Therapeutics and Vellum Biotechnology, and is a board observer for Pulmocide, Inc. Prior to his current role, Mitchell was Senior Investment Director for the Roche Venture Fund, a $750M Swiss corporate venture fund which invests for financial return. His portfolio included Pandion Therapeutics (acquired by Merck), Enliven Therapeutics (NASDAQ:ELVN), Good Therapeutics (acquired by Roche), Jasper Therapeutics (NASDAQ:JSPR) and Kumquat Biosciences. He was also a co-founder, President, Chief Scientific Officer and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company acquired by Pfizer in 2021. Mitchell was also on the founding team and Principal Scientist of Labcyte, a tools company that was acquired by Beckman Coulter Life Sciences for over $300M. Mitchell earned a Ph.D. in chemistry from the University of Rochester, a diploma in orchestral studies from the University of London, and a B.A. in chemistry with high honors from Oberlin College. Mitchell is also an inventor on 38 issued patents.